Back
Popescu I. 2025. PPARevolution. First PPARδ Agonist and a Dual PPARα/PPARδ Activator Approved for the Treatment of Primary Biliary Cholangitis. J Cell Mol Med (Nov 2025)
Pei Y, et al. 2025. Letter on 'Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis'. Aliment Pharmacol Ther (Nov 2025)
Tang X, You X. 2025. Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis. Gut Pathog (Nov 2025)
Tana MM, Hirschfield GM. 2025. Primary Biliary Cholangitis. JAMA (Nov 2025)
Lakshmanan V, Morris L. 2025. Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis. Cureus (Oct 2025)
Zhou AE, et al. 2025. Treatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib. J Drugs Dermatol (Nov 2025)
Liu C, et al. 2025. Letter: Optimizing Risk Stratification in Primary Biliary Cholangitis-The Role of Biochemical Response as a Dynamic Predictor. Aliment Pharmacol Ther (Nov 2025)
Hirschfield GM, et al. 2025. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol (Oct 2025)
Lohse AW, Assis DN. 2025. Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis. Lancet Gastroenterol Hepatol (Oct 2025)
Kowdley KV, et al. 2025. Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Oct 2025)
Kuo SZ, et al. 2025. Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Oct 2025)
Jamal F, et al. 2025. Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. Biomedicines (Sep 2025)
Ye X, et al. 2025. Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis. Ann Hepatol (Oct 2025)
Zhang M, et al. 2025. The Genomics/Genetics of Primary Biliary Cholangitis: The Case for a Functional SNP rs10893900 in ETS1/FLI1 and Review of the Literature. Clin Rev Allergy Immunol (Oct 2025)
Li J, et al. 2025. Autophagy Sustained the Activation and Survival of Liver-infiltrating CD8 T Cells in Primary Biliary Cholangitis. Immunol Invest (Oct 2025)
Tao Y, et al. 2025. The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data. Front Immunol (2025)
Ren W, et al. 2025. Identification of galangin as a therapeutic candidate for primary biliary cholangitis via systematic druggable genome-wide Mendelian randomization analysis and experimental validation. Front Pharmacol (2025)
Passos PRC, et al. 2025. Recurrent primary biliary cholangitis after liver transplantation: A global meta-analysis of epidemiology and risk factors. Am J Transplant (Oct 2025)
Harada K, et al. 2025. Histological characteristics of primary biliary cholangitis in patients with incomplete responses to ursodeoxycholic acid. Hum Pathol (Oct 2025)
Gordon SC, et al. 2025. Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis. BMJ Open Gastroenterol (Oct 2025)
Gerussi A, et al. 2025. Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER). United European Gastroenterol J (Oct 2025)
Forero Vásquez BN, et al. 2025. Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report. Cureus (Sep 2025)
Curto A, et al. 2025. Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies. World J Clin Cases (Oct 2025)
Chen R, et al. 2025. Innate immunity of bile and cholangiocytes in primary biliary cholangitis. Front Immunol (2025)
Das TS, Vuppalanchi R. 2025. Recent Advances in Primary Biliary Cholangitis Treatment. Clin Liver Dis (Nov 2025)
Shen G, et al. 2025. The effects of lifestyle factors on primary biliary cholangitis ascertained by two-sample Mendelian randomization. Am J Med Sci (Oct 2025)
Yu C, et al. 2025. Impact of the prognostic nutritional index on the recompensation of patients with decompensated primary biliary cholangitis. Front Immunol (2025)
. 2025. Correction to 'Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study'. Liver Int (Nov 2025)
Ye K, et al. 2025. Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy. Front Immunol (2025)
Herta T, et al. 2025. Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care. Ann Hepatol (Oct 2025)
Koc OM, et al. 2025. Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases. Lancet Gastroenterol Hepatol (Oct 2025)
Floreani A, et al. 2025. An update on novel investigational agents for the treatment of primary biliary cholangitis. Expert Opin Investig Drugs (Nov 2025)
Zhang J, Hirata Y. 2025. Response to "Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others?". Hepatol Res (Oct 2025)
Corpechot C, et al. 2025. Bezafibrate for primary biliary cholangitis: time to act on the evidence. Nat Rev Gastroenterol Hepatol (Oct 2025)
Arase Y, et al. 2025. Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial. Hepatol Commun (Nov 2025)
Luo H, et al. 2025. Causal association between dietary factors and Primary Biliary Cholangitis: A Mendelian randomization study. Medicine (Baltimore) (Oct 2025)
Martins A, et al. 2025. Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis. Hepatology (Jul 2025)
Wong YJ, et al. 2025. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis. J Hepatol (Oct 2025)
Ma H, et al. 2025. Profiling of circulating T follicular helper and T peripheral helper cell subsets in patients with primary biliary cholangitis. Immunol Lett (Oct 2025)
Zhang X, et al. 2025. The Depletion of Plasma Cells but Not CD20B Cells Alleviates Primary Biliary Cholangitis. Liver Int (Nov 2025)
Du Q, et al. 2025. Absence of bidirectional causality between primary biliary cholangitis and major depression: A two-sample Mendelian randomization study. Medicine (Baltimore) (Sep 2025)
Abreu ES, et al. 2025. Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis. J Gastroenterol Hepatol (Sep 2025)
Bhatnagar P, Eid N. 2025. Rapamycin nanoparticles suppress autoreactive lymphocytes and reduce anti-mitochondrial antibodies in primary biliary cholangitis: Mechanisms and implications. World J Hepatol (Sep 2025)
Liu HL, et al. 2025. Comparison of pathological features of patients with antibody-negative and positive primary biliary cholangitis. BMC Gastroenterol (Sep 2025)
Cançado GGL, et al. 2025. High biochemical remission rates in patients with primary biliary cholangitis treated with "triple" anticholestatic therapy. Hepatol Commun (Oct 2025)
Zhang Z, Yang Z. 2025. Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others? Hepatol Res (Sep 2025)
Abbas N, et al. 2025. Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Sep 2025)
Sirohi N, et al. 2025. Dismal Prognosis of Primary Biliary Cholangitis and Its Overlap with Autoimmune Hepatitis. J Clin Exp Hepatol (2025)
Nie Y, et al. 2025. Gut Microbiota: Implications in Pathogenesis and Potential Therapeutic Target in Primary Biliary Cholangitis. J Clin Transl Hepatol (Sep 2025)
Zhang W, et al. 2025. A Bibliometric Analysis of Immunological Research in Primary Biliary Cholangitis: Global Patterns and Emerging Directions. Cureus (Aug 2025)
Zhang M, et al. 2025. Genetic architecture of primary biliary cholangitis: strong evidence for HLA and non-HLA risk loci. Front Immunol (2025)
Kugiyama Y, et al. 2025. Clinical Characteristics and Long-Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd-Generation Nationwide Survey. Hepatol Res (Sep 2025)
Brice C, Louvet A. 2025. [New therapeutic approaches for the treatment of primary biliary cholangitis]. Med Sci (Paris) (2025)
Liao W, et al. 2025. Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis. Therap Adv Gastroenterol (2025)
Memon A, et al. 2025. A comprehensive review of systemic sclerosis-primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype. Curr Opin Rheumatol (Nov 2025)
Wang X, et al. 2025. Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China. Clin Rheumatol (Oct 2025)
Herta T, Berg T. 2025. [Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options]. Inn Med (Heidelb) (Sep 2025)
Pan SD, et al. 2025. MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid. World J Gastroenterol (Aug 2025)
Han HQ, et al. 2025. Peripheral basophil activation: A hidden player in the immunopathogenesis of primary biliary cholangitis. World J Hepatol (Aug 2025)
Abuelazm M, et al. 2025. The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. JGH Open (Sep 2025)
Del Barrio M, et al. 2025. Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression. Int J Mol Sci (Aug 2025)
Buck L, et al. 2025. An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis. Sci Rep (Aug 2025)
Ding D, et al. 2025. Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria. J Transl Int Med (Aug 2025)
Lu W, et al. 2026. Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis. Clin Chim Acta (Jan 2026)
Abid S, et al. 2025. Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape. Ann Med Surg (Lond) (Jul 2025)
Chen PT, Chen HW. 2025. Reply to "Comment on risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan". J Formos Med Assoc (Aug 2025)
Zeng Z, et al. 2025. Integrating Machine Learning and Multiomics Analyses to Identify Immune-Related Biomarkers and Mechanisms in Primary Biliary Cholangitis. Clin Transl Gastroenterol (Oct 2025)
Chen W, et al. 2025. Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics. Front Med (Lausanne) (2025)
Okumura T, et al. 2025. Prognostic Significance of Bile Duct Loss in Early-Stage Primary Biliary Cholangitis: A Long-Term Observational Study. Hepatol Res (Aug 2025)
Ashraf T, et al. 2025. Correction: The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis. BMC Gastroenterol (Aug 2025)
Zou M, et al. 2025. Insights into the association between primary biliary cholangitis and colorectal neoplasia: More details, more significance. J Formos Med Assoc (Aug 2025)
Li S, et al. 2025. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels. Clin Chem Lab Med (Nov 2025)
Zingone F, et al. 2025. Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Liver Int (Sep 2025)
Sierra L, et al. 2025. Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: A United States cohort. Ann Hepatol (Aug 2025)
Rogalska M, et al. 2025. Elevated Plasma BDNF in Early Primary Biliary Cholangitis: Associations with Liver Fibrosis, IL-6, IL-18, Fatigue, and Cognitive Impairment. Int J Mol Sci (Jul 2025)
Miglianti M, et al. 2025. The role of HLA-G in primary biliary cholangitis and response to therapy. Front Immunol (2025)
Said E, et al. 2025. Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation. Cureus (Jul 2025)
Zhu HL, et al. 2025. [Predictive value of neutrophil/lymphocyte ratio in the prognosis of primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jul 2025)
Ran Y, et al. 2025. [Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jul 2025)
Ma L, et al. 2025. [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension]. Zhonghua Gan Zang Bing Za Zhi (Jul 2025)
Koky T, et al. 2025. Early assessment of treatment response in primary biliary cholangitis: key to timely management. BMC Gastroenterol (Aug 2025)
Shukla AK, Misra S. 2025. Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. J Basic Clin Physiol Pharmacol (Sep 2025)
Zhang J, et al. 2025. Dendritic Cell-Depleted Mice Develop the Autoimmune Biliary Disease That Serologically and Pathogenically Models Human Primary Biliary Cholangitis. Hepatol Res (Nov 2025)
Ando Y, et al. 2025. Anti-centromere antibody positivity with coexisting idiopathic portal hypertension and primary biliary cholangitis progressing to limited cutaneous systemic sclerosis: a case report. J Med Case Rep (Aug 2025)
Kobayashi Y, et al. 2025. Acute-on-chronic liver failure in primary biliary cholangitis by exacerbation of autoimmune hepatitis features. Clin J Gastroenterol (Oct 2025)
Lei X, et al. 2025. A case of membranous nephropathy complicated by autoimmune hepatitis and primary biliary cholangitis. Medicine (Baltimore) (Aug 2025)
Haddadin R, et al. 2025. Diagnostic Challenges in Concurrent Primary Biliary Cholangitis and Secondary Syphilis: A Case Report. J Community Hosp Intern Med Perspect (2025)
Li SX, et al. 2025. GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate. J Dig Dis (May 2025)
Zang B, et al. 2025. Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis. World J Hepatol (Jul 2025)
Mitchell NE, et al. 2025. Evolving therapeutic landscape of primary biliary cholangitis: A review. World J Hepatol (Jul 2025)
Gelhorn H, et al. 2025. Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis. Orphanet J Rare Dis (Jul 2025)
Ren W, et al. 2025. Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis. BMC Gastroenterol (Jul 2025)
Floreani A, et al. 2025. Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis. Expert Rev Gastroenterol Hepatol (Aug 2025)
Cho EJ. 2025. Emerging Therapeutics for Primary Biliary Cholangitis. Korean J Gastroenterol (Jul 2025)
Rogalska M, et al. 2025. Clinical characteristics of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Pol Arch Intern Med (Sep 2025)
Pu X, et al. 2025. B cells drive CCR5CD4 tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis. J Hepatol (Nov 2025)
Abulitifu Y, et al. 2025. The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial. BMC Gastroenterol (Jul 2025)
Wei Y, et al. 2025. Postpartum may be a risk factor for biochemical flares in patients with primary biliary cholangitis: A single-center experience. Clin Rheumatol (Sep 2025)
Rigopoulou EI, et al. 2025. IgG Baseline Serum Levels and Prognosis of Primary Biliary Cholangitis. Liver Int (Aug 2025)
Khadijat-Ul-Kurba H, et al. 2025. Atorvastatin unveiling primary biliary cholangitis and autoimmune hepatitis overlap syndrome in an older adult: A case report. Malays Fam Physician (2025)
URSO Calculator
Jul 27th, 2025 The PBC Ireland Patient Registry is now LIVE!
Jul 26th, 2025 PBC Ireland will attend Global Liver Institute's A3 Program in Washington, DC
May 8th, 2025 PBC Ireland Launched!
© PBC Ireland 2025 - 2025 | Terms | Privacy & GDPR
